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SM22a is an adult smooth muscle-speci®c protein that is expressed in the smooth, cardiac, and skeletal muscle
lineages during early embryogenesis before becoming restricted speci®cally to all vascular and visceral smooth muscle
cells (SMC) in late fetal development and adulthood. We have used the SM22a gene as a marker to de®ne the regulatory
mechanisms that control muscle-speci®c gene expression in SMCs. Previously, we reported that the 445-base-pair
promoter of SM22a was suf®cient to direct transcription of a lacZ reporter gene in early cardiac and skeletal muscle
cell lineages and in a subset of arterial SMCs, but not in venous nor visceral SMCs in transgenic mice. Here we
describe two evolutionarily conserved CArG (CC(A/T)6GG) boxes in the SM22a promoter, both of which are essential
for full promoter activity in cultured SMCs. In contrast, only the promoter-proximal CArG box is essential for speci®c
expression in developing smooth, skeletal, and cardiac muscle lineages in transgenic mice. Both CArG boxes bind
serum response factor (SRF), but SRF binding is not suf®cient for SM22a promoter activity, since overexpression of
SRF in the embryonal teratocarcinoma cell line F9, which normally expresses low levels of SRF, fails to activate the
promoter. However, a chimeric protein in which SRF was fused to the transcription activation domain of the viral
coactivator VP16 is able to activate the SM22a promoter in F9 cells. These results demonstrate the SM22a promoter-
proximal CArG box is a target for the regulatory programs that confer smooth, skeletal, and cardiac muscle speci®city
to the SM22a promoter and they suggest that SRF activates SM22a transcription in conjunction with additional
regulatory factors that are cell type-restricted. q 1997 Academic Press
pression (Owens, 1995). It is also unclear whether there areINTRODUCTION
muscle gene regulatory programs that are shared by multi-
ple muscle cell types or whether muscle genes that are ex-The three major muscle cell types, skeletal, cardiac, and
pressed in multiple muscle cell types respond to myogenic
smooth, express overlapping sets of muscle-speci®c genes regulatory programs unique to each muscle type.
during development. Whereas several transcription factors
SMCs are highly diverse with respect to their contractile,
required for skeletal and cardiac muscle gene expression
electrophysiological, and pharmacological properties ashave been identi®ed (Olson, 1993; Olson and Srivastava,
well as embryonic origins (Schwartz et al., 1990; Akerlund,1996), little is known of the transcriptional mechanisms
1994; Zingg et al., 1995). Arterial and venous SMCs withinthat regulate smooth muscle cell (SMC)-speci®c gene ex-
the vasculature, for example, exhibit distinct properties and
are clearly different from the many types of visceral SMCs
within the digestive, respiratory, and genitourinary sys-1 To whom correspondence should be addressed. Fax: (214) 648-
1196. E-mail: eolson@hamon.swmed.edu. tems. This diversity of SMCs may account for the func-
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tional diversity of SMCs in many different physiological control gene expression in the skeletal, cardiac, and smooth
muscle lineages.processes. Identi®cation of the regulatory mechanisms that
In this study, we show that SM22a transcription is depen-control gene expression in these distinct SMCs should lead
dent on an evolutionarily conserved CArG box in the pro-to a better understanding at a molecular level of SMC prolif-
moter. Although this CArG box binds SRF, SRF alone iseration, differentiation, and determination during em-
insuf®cient for SM22a promoter activation. Rather, our re-bryogenesis.
sults suggest that SRF-dependent activation of SM22a tran-We have used the SM22a gene as a marker for elucidating
scription requires an additional factor that can be bypassedthe mechanisms that regulate muscle gene expression in
by fusion of the viral coactivator VP16 to the SRF DNASMCs. SM22a is a calponin-related protein that is speci®c
binding domain. Our results demonstrate that CArG box-to adult SMCs (Duband et al., 1993). During mouse em-
binding factors control SM22a transcription in arterialbryogenesis, SM22a is expressed transiently in the cardiac
smooth, skeletal, and cardiac muscle cells and are consis-and skeletal muscle lineages before becoming restricted to
tent with a model in which SRF acts through a combinato-SMCs during late fetal development (Li et al., 1996a). Re-
rial mechanism with a myogenic cofactor(s) to control mus-cently, we showed that the 445-base-pair promoter of
cle gene expression through this site.SM22a was suf®cient to direct the expression of a linked
reporter gene in the smooth, cardiac, and skeletal muscle
lineages of transgenic mice (Li et al., 1996b). However, in
contrast to the endogenous SM22a gene which is expressed MATERIALS AND METHODS
in all SMC types throughout development, this region of
the promoter was active only in a subset of arterial SMCs, Cloning of the SM22a promoter from chick and human librar-
but not venous nor visceral SMCs. Within the developing ies. Human or chicken SM22a gnomic clones were isolated by
heart, this promoter was active only in the bulbus cordis, screening an RPMI8402 human gnomic library (Baer et al., 1988)
or CL1012j chicken genomic library (Clonetech, Palo Alto, CA)not in the left ventricle, nor atria (Li et al., 1996b). These
using the 1078-bp mouse SM22a cDNA (Li et al., 1996b) as a proberesults have been con®rmed by others (Moessler et al.,
under the following low-stringency conditions. Brie¯y, the gnomic1996). The ®nding that the SM22a promoter directed ex-
libraries were lifted in duplicate onto nitrocellulose ®lters thatpression to a subset of SMC types, whereas the endogenous
were then baked at 807C under vacuum for 2 hr. After prehybridiza-
gene was expressed throughout diverse SMC types, indi- tion for 4 hr at 427C in a solution containing 35% formamide, 51
cated that separate regulatory elements govern SM22a tran- SSC, 51 Denhardt's solution, 0.05 M NaHPO4, pH 7.0, 0.1% SDS
scription in different SMC types and suggested that different and 100 mg/ml of salmon sperm DNA, the ®lters were hybridized
regulatory programs are utilized to control expression of overnight in similar solution, but with the following modi®cations,
20% formamide, 10% dextran sulfate, and without SDS. Filtersthis gene in different tissues during embryogenesis.
were washed in 21 SSC, 0.1% SDS solution twice (20 min eachThe region of the SM22a promoter that directs expression
time), and once in 0.51 SSC, 0.1% SDS at 507C. The ®lters werein transgenic mice contains two CArG (CC(A/T)6GG)
then exposed to X-ray ®lms (Kodak) at 0707C overnight. Duplicateboxes, which were ®rst identi®ed as important regulatory
positive clones were picked for secondary and tertiary screening.
elements in the cardiac and skeletal a-actin gene promoters The sequences for the human and chicken SM22a proximal pro-
(Gustafson et al., 1988; Grichnik et al., 1988). Subsequently, moters were determined using primers from the 5* untranslated
CArG boxes were found to be among essential regulatory regions of the corresponding human and chicken cDNA sequences.
elements in the promoters of a number of cardiac, skeletal, DNA sequences of both strands were determined by automated
sequencing. Sequence alignment was performed using the Geneticand smooth muscle genes (Owens, 1995; Lee et al., 1991;
Computer Group (GCG) software package (University of TexasMiwa et al., 1987; Mohun et al., 1989; Walsh, 1989; Catala
Southwestern Medical Center).et al., 1995; Yano et al., 1995; Wang et al., 1994; Katoh et
Oligonucleotide synthesis and site-directed mutagenesis.al., 1994; Goswami et al., 1994; Argentin et al., 1994;
Oligonucleotides encompassing the CArG-near or CArG-farAmacher et al., 1993; Chow and Schwartz, 1990). The CArG
boxes and 10±15 nucleotides of ¯anking sequence were synthesized
box binds serum response factor (SRF), a member of the by Genosynthesis Inc. (Houston, TX). For convenience, an EcoRI
MADS (MCM1, agamous, de®ciens, serum response factor) or HindIII site was introduced into the mutant CArG boxes. The
box family of transcription factors (Shore and Sharrocks, mutated oligonucleotides were synthesized with 5*-phosphoryla-
tion and puri®ed on polyacrylamide gels. The sequences of synthe-1995; Treisman and Ammerer, 1992). SRF is expressed in a
sized oligonucleotides were as follows (the CArG boxes are under-variety of muscle and nonmuscle cells (Shore and Sharrocks,
lined and the mutated bases are bolded and italized):1995). However, it is highly restricted to cardiac, skeletal,
and smooth muscle lineages during avian embryogenesis
CArG-near oligo: 5*-AACTTGGTGTCTTTCC(Croissant et al., 1996). Transcriptional regulation by SRF
has been shown to require combinatorial interactions with CCAAATATGGAGCCTGTGTGGAGTG
accessory factors (Chow and Schwartz, 1990; Treisman,
1994; Macleod et al., 1992; Hill et al., 1993; Chen and CArG-near-mutant oligo: 5*-GGTGTCTTTCC
Schwartz, 1996; Grueneberg et al., 1992) raising the possi-
CGAATTCTGGAGCCbility that myogenic cofactors may cooperate with SRF to
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CArG-far oligo: 5*-GGTTTCAGGGTCCTGC pSM1343lacZ (Li et al., 1996b) with mutations at the CArG-near
or CArG-far box, respectively, were digested with NotI and HindIII
CCATAAAAGGTTTTTCCCGGCCGCC to eliminate bacterial vector sequences. The DNA fragments for
injection were puri®ed by Qui-quick column and resuspended in
CArG-far-mutant oligo: 5*-GGGTCCTGC injection buffer (Cheng et al., 1992). Methods for transgenic mice
generation and detection were described previously (Li et al., 1996b;CAATAAAAGCTTTTT
Cheng et al., 1992). To detect the expression of the lacZ transgene,
transgenic embryos were isolated at E11.5 and the yolk sacs were
The mutants were generated initially in the Bluescript vector, saved to detect transgene integration by Southern analysis or PCR.
containing a region of the SM22a promoter extending from the The embryos were ®xed in 2% formaldehyde for 30 min and rinsed
transcription initiation site to 01343bp, using the Chameleon mu- with 11 PBS for 1 hr before staining for b-galactosidase activity.
tagenesis kit (Stratagene). To analyze the effects of introduced mu- To better visualize the vasculature of the embryo, stained embryos
tations on the SM22a promoters, the mutated promoters were were dehydrated in 100% methanol for 2 days and cleared in a
cloned into the same promoterless vectors containing lacZ or lucif- solution of benzyl benzoate and benzyl alcohol (2:1 by volume) for
erase as reporters (Li et al., 1996b). 1±3 hr before photography. For histology, X-gal-stained embryos
Transfection and luciferase assay. To determine the transcrip- were embeded in paraf®n after gradual dehydration in ethanol and
tional activities of the mutated SM22a promoters, the rat PAC1 washing in xylene. Embryos were sectioned at 7 mm per section and
(pulmonary artery cell) SMC cell line (gift from Dr. S. Schwartz), counterstained with hematoxylin and eosin (Laboratory of Clinical
primary SHR rat aortic SMCs, C2 skeletal myoblasts, and F9 cells Pathology, Harper Hospital, Wayne State University).
were seeded in 6-cm dishes for transfection. After 24 hr, cells were
transfected in 10% fetal bovine serum (FBS) at about 70% con¯u-
ency except for F9 cells, which were at about 50% con¯uency. The
pSM1343-luc plasmid contains 1343 bp of the SM22a promoter RESULTS
linked to the luciferase reporter gene (Li et al., 1996a). In plasmid
SRF-VP16, amino acids 411±490 of herpes simplex virus protein,
Evolutionary conservation of the SM22a promoter. WeVP16, were fused to the N-terminus of full-length SRF (Grueneberg
reported previously that the region from 0445 to /62 ofet al., 1992). Both SRF and SRF-VP16 were in pCGN vectors (Ta-
the mouse SM22a gene was suf®cient to direct expressionnaka et al., 1990). Then 2.5 to 5 mg of each luciferase reporter
of a linked lacZ transgene in a subset of arterial SMCsplasmid was transfected by calcium phosphate precipitation.
Brie¯y, cells were fed with 5 ml 10% FBS 3 hr before transfection. throughout pre- and postnatal development and transiently
Plasmid DNA together with 31 ml of 2 M CaCl2 was brought to a in the cardiac and skeletal muscle lineages during mouse
®nal volume of 250 ml with water and was then added dropwise to embryogenesis (Li et al., 1996b). To begin to de®ne the cis-
250 ml of 21 HBS (pH 7.12) which was made from 101 HBS [8.18% acting elements within this region of the SM22a promoter
NaCl (w/v), 5.94% Hepes (w/v), 0.2% Na2HPO4 (w/v)]. The precipi- that were required for transcriptional activity in these dif-
tate was formed immediately and then added to medium in the ferent muscle cell types, we isolated the chicken and human
dish. After incubation for 8 hr at 377C, the medium was changed
SM22a genes and compared the sequences of the promoterswith fresh 10% FBS and the cells were harvested 48 hr later. The
from the different species. The sequence of the rat promoterluciferase assay was performed as described by manufacturer's in-
has also been published (Osbourn et al., 1995). The SM22astructions (Promega luciferase assay kit). All experiments were re-
promoters from the different species showed relatively highpeated at least three times and the relative luciferase activities
(RLU) were normalized to equal amounts of protein. homology within the ®rst 389 bp upstream of the transcrip-
Nuclear extract isolation and gel mobility shift assays. To test tion initiation site (Fig. 1A), whereas further upstream of
for CArG-box±DNA binding activities, nuclear extracts were iso- this region they diverged. Within the conserved region, two
lated from cultured SMCs, C2 myotubes, and F9 cells as described of the most conserved segments of homology corresponded
(36). SHR aortic SMCs and F9 cells were cultured in 10% FBS to CArG boxes, CC(A/T)6GG, which have been shown toand harvested at con¯uency. C2 cells were harvested 2 days after play important roles in regulation of the smooth muscle
switching into 2% FBS. Then 10 pmol of double-stranded oligonu-
(SM) a-actin gene, as well as several cardiac and skeletalcleotides was end-labeled by 32P using T4 kinase (Boehringer-
muscle genes (Owens, 1995; Lee et al., 1991; Miwa andMannhein Biochemicals). About 0.01 pmol of probe was used in
Kedes, 1987; Mohun et al., 1989; Walsh, 1989; Catala et al.,each reaction with 1 mg of nuclear extract or GST±SRF protein (a
1995; Yano et al., 1995; Wang et al., 1994; Katoh et al.,gift from Dr. R. Schwartz) that had been puri®ed on a GST af®nity
column. This fusion protein contains the full-length SRF protein 1994; Goswami et al., 1994; Argentin et al., 1994; Amacher
fused to the C-terminus of glutathione-S-transferase (Chen and et al., 1993; Chow and Schwartz, 1990).
Schwartz, 1996). Antibody supershift experiments included 1 ml of The sequences surrounding the SM22a promoter-proxi-
anti-SRF antibody (a gift from Dr. R. Schwartz) or preimmune se- mal CArG box, referred to as CArG-near, were also con-
rum as a control. Competition experiments included 1 pmol of served across species and shared high homology with the
unlabeled oligonucleotides as competitors. The conditions for the sequences adjacent to the promoter-proximal CArG box
binding reactions were described previously (Cserjesi et al., 1994).
from the SM a-actin gene (Fig. 1B) (Foster et al., 1992; Shim-DNA±protein complexes were resolved on 5% polyacrylamide gels
izu et al., 1995), raising the possibility that common SRF(acrylamide:bisacrylamide, 30:0.8).
accessory factors may bind these sequences. This ®nding isGeneration of transgenic mice. To test SM22a promoter activi-
intriguing given that activation of c-fos transcription by SRFties in vivo, DNA plasmids SM1343CArG-near-mut-lacZ and
SM1343CArG-far-mut-lacZ, that were derived from the plasmid involves interaction of SRF with accessory factors that rec-
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FIG. 1. Evolutionary conservation of SM22a promoter sequences. (A) The sequences of the SM22a promoters from mouse, rat, human,
and chicken are compared. A dash indicates identity with the mouse sequence. The promoter sequences diverge upstream of 0389 bp of
the mouse sequence and the chick promoter sequence diverges from the mammalian promoter sequences downstream of 0104 bp. The
CArG-far, CArG-near, and TATA-like sequences are boxed. Sequences from mouse and rat are numbered relative to the transcription
initiation site. The transcription initiation site has not been reported for the human or chick genes; nucleotides for these species are
therefore unnumbered. GenBank accession numbers for the chick and human sequences are AF009174 and AF009175, respectively. (B)
Comparison of CArG-near and surrounding sequences with a homologous region from the mouse SM a-actin promoter.
ognize sequences ¯anking the CArG box, also referred to We also tested nuclear extracts from a variety of cell lines
for binding to the CArG-near and CArG-far regions. Severalas the serum response element (SRE) (Hill et al., 1994).
Binding of SRF to the SM22a promoter. To determine DNA±protein complexes were observed using labeled
CArG-near and CArG-far probes with nuclear extracts fromwhether the CArG boxes in the SM22a promoter could bind
SRF, we initially performed gel mobility shift assays using SHR SMCs and C2 skeletal myotubes (Figs. 2B and 2C),
both of which support activation of the SM22a promoter.a bacterially expressed GST±SRF fusion protein and 32P-
labeled probes corresponding to the CArG-near and CArG- To test whether SRF was contained in any of these com-
plexes, SRF antibody was included in certain of the bindingfar boxes and their ¯anking sequences. SRF bound avidly
to both sequences (Fig. 2A), yielding a complex with similar reactions. In the presence of the antibody, the slowest mi-
grating complex was supershifted to the top of the gel, indi-mobility to that seen using the c-fos SRE as a probe with
GST±SRF or SMC nuclear extracts. cating that this complex contained SRF (Fig. 2B, lanes 2 and
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FIG. 2. Binding of SRF to CArG-near and CArG-far sequences. Oligonucleotide probes encompassing CArG-near and CArG-far and their
¯anking sequences or the c-fos SRE, as indicated (see Materials and Methods), were used in gel mobility shift assays with GST±SRF (A)
and with nuclear extracts from the indicated cell lines (B, C). The position of the SRF-containing complex is shown in each panel and
competitors and antibodies used in each reaction are shown. The bottom of the gel was removed from A. The arrowhead adjacent to lane
10 in C indicates the position where the SRF- containing complex, which is absent in F9 cells, would migrate. CArG n, CArG-near;
CArGn0, CArG-near mutant; CArGf, CArG-far.
7; Fig. 2C, lanes 2 and 8). Preimmune serum had no effect sion of a luciferase reporter gene in transfected PAC1 cells
and primary SHR aortic SMCs. The 1343 bp promoter inon the SRF-containing complex (not shown). The SRF-con-
taining complex was readily detectable in SMCs and C2 the reporter construct pSM1343-luc was transcriptionally
active in PAC1 cells (Fig. 3), as well as in primary SMCs (notmyotubes (Fig. 2B, lanes 1 and 6; Fig. 2C, lanes 1 and 7). In
contrast, this complex was barely detectable, if at all, in F9 shown). Mutation of either of the CArG boxes signi®cantly
reduced the activity of the promoter, suggesting that bothcells (Fig. 2B, lane 8; Fig. 2C, lane 9), in which the SM22a
promoter is inactive (Li et al., 1996b). CArG boxes are required for full transcriptional activity of
the SM22a promoter in tissue culture.The SRF-containing complex was abolished in the pres-
ence of unlabeled oligonucleotides corresponding to the c- Differential requirements of CArG-near and CArG-far
boxes for SM22a transcription in developing myogenic lin-fos SRE or the CArG-near and CArG-far sequences (Fig. 2B,
lanes 3 and 4; Fig. 2C, lanes 3±5). In addition to SRF, there eages in vivo. We also investigated the potential impor-
tance of the two CArG boxes for SM22a promoter activityappeared to be other factors that bound speci®cally to the
CArG-far and CArG-near probes. The factors involved in in transgenic mice by comparing the expression of a lacZ
reporter gene linked to the wild-type 1343-bp promoter orformation of these complexes appeared to be speci®c for
sequences unique to each probe since they were speci®cally mutant promoters in which each CArG box had been al-
tered. The activity of these constructs was examined incompeted by the cognate unlabeled probe, but not by the
c-fos SRE or the opposite CArG oligonucleotides (Figs. 2B founder transgenic mice at E11.5. As reported previously
(Li et al., 1996b; Moessler et al., 1996), the SM22a promoterand 2C, compare lane 1 with lanes 3, 4, and 5). This result
indicated that there were factors in addition to SRF binding directed transcription in the developing vasculature and
heart tube, as well as in skeletal muscle cells of the somiteto the ¯anking sequences of the CArG box regions, which
might be involved in regulation of SM22a gene expression. myotome at E11.5 (Figs. 4A and 4D). We analyzed four inde-
pendent transgenic embryos harboring the transgeneBoth CArG boxes are required for full activity of the
SM22a promoter in cultured SMCs. To examine whether SM1343CArG-far-mut-lacZ, in which CArG-far had been
mutated; all of the embryos showed expression patterns inthe CArG boxes in the SM22a promoter were important for
transcription, we mutated each CArG box individually in the arterial vasculature similar to those of embryos harbor-
ing the wild-type transgene. This mutant transgene was alsothe context of the 1343-bp promoter and assayed the abili-
ties of the wild-type and mutant promoters to drive expres- expressed in myotomes of the somites, but expression in
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vector was not suf®cient to activate the promoter in F9
cells, indicating that the lack of SRF expression in these
cells cannot by itself account for the failure of the SM22a
promoter to be expressed.
There are at least two potential mechanisms that could
account for the inability of exogenous SRF to activate the
SM22a promoter in F9 cells. SRF could be inactive in this
cell type, by a block to DNA binding, for example, or F9
cells could lack cofactors required by SRF for SM22a pro-
moter activation. In an attempt to distinguish between
these possibilities, we tested whether SRF±VP16, in which
the activation domain of the viral protein VP16 was fused
to the N-terminus of the full-length SRF (Grueneberg et al.,
1992), could activate the SM22a promoter to in F9 cells.
Indeed, SRF-VP16 activated the SM22-luciferase reporter inFIG. 3. Effects of CArG box mutations on SM22a promoter activ-
F9 cells (Fig. 5). The effects of SRF±VP16 were speci®c fority in transfected cells. The wild-type reporter gene SM1343-luc or
the SM22a promoter because pSV-luc, which contains thethe same reporter with mutations in either CArG-near or CArG-
SV40 promoter, was not responsive to SRF±VP16. Thesefar were transfected into the PAC1 SMC line and luciferase activi-
results demonstrate that SRF can bind DNA in F9 cells andties were determined as described under Materials and Methods.
The results represent the averages of two independent experiments they suggest that an additional factor(s) required for SRF-
and are expressed as the percentage of maximal expression observed mediated transcriptional activation of the SM22a promoter
with SM1343-luc. is lacking in F9 cells.
DISCUSSION
the myotomes was limited to one or two cell layers (Fig.
4B). Although the lacZ gene was expressed in the bulbus SM22a is expressed in all SMC types throughout pre- and
postnatal development and transiently in the cardiac andcordis of the heart at E11.5, expression was not detected in
the trabeculae of the myocardium, but was limited to the skeletal muscle lineages during embryogenesis (Li et al.,
1996a). Thus, de®ning the mechanisms that regulate SM22awall of the conus arteriosus within the bulbus cordis where
the spirally aortic and pulmonary channels were forming transcription should lead to an understanding of the similar-
ities and differences in the regulatory programs for muscle(Figs. 4B and 4E). Among these four transgenic embryos,
there was only one that showed additional ectopic expres- gene expression in these different muscle cell types. The
ability of the proximal SM22a promoter to direct transcrip-sion in the apical ectodermal regions of the limbs. Because
we have never seen this ectopic expression pattern in other tion speci®cally in arterial but not in venous nor visceral
SMCs also provides an opportunity to de®ne the regulatoryembryos, we believe that it re¯ects a positional effect of
transgene integration. programs that distinguish these different types of SMCs.
Regulation of SM22a transcription by CArG box-bind-In contrast to the apparently normal expression pattern
of the CArG-far-mutant promoter in vascular SMCs, we ing factors. Our results demonstrate that activation of
SM22a transcription by SRF is mediated by two evolution-never observed expression of the transgene SM1343CArG-
near-mut-lacZ, in which CArG-near was altered, in any arily conserved CArG boxes in the SM22a promoter.
Whereas both sites are important for transcriptional activa-muscle cell lineage (Fig. 4C). A total of 16 embryos were
shown to be positive for transgene integration by both PCR tion of the gene in cultured SMCs, they contribute differ-
ently to the temporospatial expression pattern of the SM22aand Southern analysis. In only one embryo with this
transgene did we observe ectopic expression of lacZ in the promoter in transgenic mice. While the proximal CArG box,
CArG-near, appears to be essential for SM22a expression inforebrain (not shown). These results demonstrate that the
two CArG boxes in the SM22a promoter play distinct roles smooth, skeletal, and cardiac muscle cells, the distal CArG
box, CArG-far, is important for the expression in the myo-in the control of SM22a transcription in vivo and they re-
veal an important role for SRF (or other CArG box-binding cardium of the bulbus cordis and in the myotome. These
results reveal distinct roles of the two SM22a CArG boxesfactors) in the control of SM22a transcription in developing
skeletal, cardiac, and smooth muscle cell lineages. in governing gene expression in different regions of the em-
bryo. Since mutations that abolish binding of SRF to theSRF alone is insuf®cient for activation of the SM22a pro-
moter. To investigate whether SRF was suf®cient to acti- SM22a CArG boxes result in altered promoter activity, we
favor the conclusion that SRF is a key regulator of the genevate the SM22a promoter, we tested whether expression of
SRF in F9 cells would lead to activation of an SM22a-lucifer- in different myogenic lineages. The differential require-
ments of the two CarG boxes in different myogenic lineagesase reporter gene containing the 2763-bp SM22a promoter.
As shown in Fig. 5, cotransfection of an SRF expression could re¯ect the association of SRF with different cofactors.
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FIG. 4. Expression patterns of wild-type and mutant SM22a-lacZ transgenes in 11.5-day embryos. LacZ reporter genes linked to the wild-
type 1343 bp SM22a promoter (A, D) or the same region with mutations in either CArG-far (B, E) or CArG-near (C) were used to generate
F0 transgenic mouse embryos, which were stained for LacZ activity. (A) LacZ activity was detected in the bulbus cordis (bc), major arterial
vasculature (a), and somites (so). (B) The 1343-bp promoter with a mutation in CArG-far directed LacZ activity in the major arterial
vasculature and the bulbus cordis and to a low level in the somite. However, expression in the bulbus cordis was restricted to the spiral
out¯ow tract (ot) where aortic±pulmonary channels are forming. (C) No LacZ activity was detected in embryos bearing the transgene
with a mutation in the CArG-near box. (D) Transverse section through the heart region of an 11.5-day embryo harboring the wild-type
reporter revealed LacZ expression in the trabeculated myocardium (tb). (E) Mutation at the CArG-far box abolished lacZ expression in
the trabeculated myocardium (tb) and lacZ expression was limited to the wall of the aorticopulmonary channels (apc). lv, left ventricle;
brd, bulbar ridge; da, descending aorta.
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and smooth muscle cell lineages during embryogenesis
(Croissant et al., 1996; R. Schwartz, personal communica-
tion). However, the SM22a promoter is active in only a
subset of myogenic cells in which SRF is expressed. The
SM22a promoter is expressed transiently in skeletal muscle
cells in the myotome, whereas SRF continues to be ex-
pressed in differentiating skeletal muscle (Croissant et al.,
1996). Similarily, the SM22a promoter is active only tran-
siently in the bulbus cordis (the future right ventricle), but
not in the left ventricular region of the heart, whereas SRF
has been shown to be expressed throughout the developing
heart during avian embryogenesis (Croissant et al., 1996).
This apparent disparity between SRF expression and SM22a
promoter activity indicates that SRF is not suf®cient for
SM22a activity. Moreover, since SRF is not strictly muscle-
speci®c, it alone cannot account for the highly speci®c ex-
pression pattern of the SM22a promoter. We therefore favor
FIG. 5. Activation of the SM22a promoter in F9 cells by SRF-
a model in which SRF cooperates with a cell-type-restrictedVP16. F9 cells were transiently transfected with a luciferase re-
cofactor to activate SM22a transcription. Such a cofactorporter gene lacking a promoter (luc) or under control of the SV40
could, in principle, be unique to each muscle lineage orpromoter (SV-luc) or 2763 bp SM22a promoter (SM22-luc) and ex-
there could be a common myogenic cofactor for SRF thatpression vectors encoding either SRF or SRF±VP16. Two days after
is expressed in multiple muscle cell types.transfection, cells were harvested and luciferase activities were de-
termined. The results represent the averages of duplicate transfec- Evidence for SRF cofactors in the regulation of SM22a
tions and are expressed as the level of expression relative to luc. transcription. The SM22a promoter was transcriptionally
Values did not vary by more than 10% of the mean. The SV40 silent in F9 cells, which express very low levels of SRF.
promoter in pSV-luc is expressed at a low level in F9 cells and is Forced expression of SRF in F9 cells failed to activate a
not responsive to SRF±VP16. reporter gene linked to the SM22a promoter, which demon-
strates that SRF alone cannot account for cell-type-speci®c
activity of the SM22a promoter. However, an SRF±VP16
fusion protein can activate the SM22a promoter in trans-However, it is formally possible that another as yet uniden-
ti®ed factor acts through the CArG boxes independent of fected F9 cells. These results demonstrate that SRF is capa-
ble of binding the CArG box in F9 cells and they suggestSRF. SRF, binding to both CArG-far and CArG-near boxes,
might therefore interact with different accessory factors to that an additional cell-type-restricted factor that is lacking
in F9 cells is required for SRF-dependent activation of theactivate transcription in different myogenic lineages.
CArG boxes have also been shown to play important roles SM22a promoter. Apparently, the strong activation domain
of VP16 (Grueneberg et al., 1992) can bypass the require-in regulation of many smooth, cardiac, and skeletal muscle
genes in cultured cells (Owens, 1995; Lee et al., 1991; Miwa ment for this coactivator.
The possibility that SRF cooperates with other tissue-and Kedes, 1987; Mohun et al., 1989; Walsh, 1989; Catala
et al., 1995; Yano et al., 1995; Wang et al., 1994; Katoh et restricted cofactors to control muscle gene expression is
consistent with the mechanism by which SRF confers se-al., 1994; Goswami et al., 1994; Argentin et al., 1994;
Amacher et al., 1993; Chow and Schwartz, 1990), but few rum-inducibility to the c-fos promoter. In that case, SRF
has been shown to act in combination with other accessorystudies have examined the contributions of CArG boxes to
muscle gene activation during embryogenesis. The SM a- factors, referred to as ternary complex factors (TCFs), that
recognize sequences adjacent to the SRE (Hill and Treisman,actin promoter contains two CArG boxes that are required
for transcriptional activity in cultured SMCs (Shimizu et 1995; Hipskind and Nordheim, 1991). TCFs, which belong
to the ets family of transcription factors, fail to bind theseal., 1995; Sun et al., 1995; Cogan et al., 1995). The promot-
ers of the smooth muscle myosin heavy chain (Katoh et al., ¯anking sequences alone, but in the presence of SRF they
make speci®c DNA contacts with a site immediately adja-1994) and caldesmon (Yano et al., 1995) genes, which are
expressed speci®cally in SMCs, also contain CArG boxes, cent to the SRE (Price et al., 1995; Treisman and Ammerer,
1992; Dalton et al., 1993). It is interesting to note that therebut their potential roles in regulation of these genes have
not yet been examined. CArG boxes have also been shown is a consensus binding site for Ets proteins, GGA(A/T), im-
mediately adjacent to the proximal SM22a CArG box. Theto be important for transcription of the a-cardiac and a-
skeletal actin genes in culture (Gustafson et al., 1988; Shore MADS domain of SRF also interacts with the homeodomain
protein Phox/MHox (Grueneberg et al., 1995), which is ex-and Sharrocks, 1995).
How might SRF regulate SM22a transcription? SRF is pressed at high levels in muscle cells (Cserjesi et al., 1992).
Recent studies have shown that the cardiac homeodomainexpressed at high levels in cultured SMCs (Shimizu et al.,
1995; and this study) and in developing skeletal, cardiac, protein Nkx-2.5 also interacts with the MADS domain of
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SRF, resulting in cooperative transcriptional activation (Lilly et al., 1995). These ®ndings have led to the conclusion
that MEF2 is an essential component of the regulatory pro-(Chen and Schwartz, 1996). SRF has also been shown to
interact with members of the MyoD family of skeletal-mus- grams that control differentiation of muscle cells from mul-
tiple lineages. The SM22a promoter does not contain a con-cle-speci®c basic helix±loop±helix (bHLH) proteins (Grois-
man et al., 1996). sensus MEF2 site. However, recent studies have revealed
that the SM22a is not expressed in the vasculature ofThere is also evidence for factors that interfere with the
activity of SRF. Activation of the a-skeletal actin promoter MEF2C-null embryos (Q. Lin, J. Schwarz, and E. Olson, un-
published), suggesting that MEF2C may regulate this pro-by SRF, for example, is inhibited by the transcription factor
YY1, which binds a site overlapping the CArG box (Lee et moter through an indirect pathway. Such regulation could
occur through the association of MEF2C with other SM22aal., 1994). In undifferentiated skeletal myoblasts, in which
YY1 is expressed at high levels, SRF is precluded from bind- promoter-binding factors or it could be mediated by other
myogenic factors that are regulated by MEF2C.ing to the promoter, whereas following initiation of differ-
entiation, YY1 is downregulated, thereby allowing SRF ac- Multiplicity of SMC transcriptional regulatory pro-
grams. Dissection of the SM22a promoter has revealedcess to its binding site (Lee et al., 1994). In the SM22a
promoter, YY1 can bind to the CArG-near, but not the unexpected diversity in the regulatory mechanisms that
control SMC gene expression. While we have identi®ed theCArG-far, region (L. Li, unpublished observations). The role
of YY1 in regulating the SM22a promoter remains to be regulatory region responsible for activation of SM22a tran-
scription in arterial SMCs, we have not yet located the re-determined.
Overlapping expression patterns of smooth, cardiac, and gion(s) that direct expression in venous or visceral SMCs.
SMCs exhibit a high degree of developmental plasticityskeletal muscle genes. Several smooth muscle genes, in-
cluding SM22a, calponin, and SM a-actin, are transiently and can intercovert between proliferative and differentiated
states in response to external stimuli. Dysregulation ofexpressed in the cardiac and skeletal muscle lineages during
embryogenesis before becoming restricted to SMCs (Li et SMC proliferation and differentiation is associated with a
variety of vascular diseases, including atherosclerosis andal., 1996a; Miano et al., 1994; Ruzicka and Schwartz, 1988).
This may indicate that the contractile and electrophysiolog- hypertension (Schwartz et al., 1995). SM22a appears to re-
spond to stimuli that modulate SMC proliferation becauseical properties of cardiac and skeletal muscle cells resemble
those of SMCs early in development. Indeed, the primative SM22a expression is detected in differentiated arterial
SMCs within the tunica media, but not within proliferativecardiac tube, which expresses smooth muscle genes, resem-
bles a vessel. SMCs within atherosclerotic plaques. Further analysis of
the regulation of this promoter should yield insights intoMembers of the MyoD family of bHLH proteins activate
gene expression in the skeletal muscle lineage by binding the regulatory mechanisms that modulate SMC phenotypes
and should reveal the mechanisms that specify the identi-the E box consensus sequence in the control regions of mus-
cle-speci®c genes (Weintraub et al., 1994; Olson, 1990). ties of different SMC types.
There are no E boxes in the region of the SM22a promoter
that directs expression in the myotome. Thus, this muscle
gene is not a direct target for transcriptional activation by ACKNOWLEDGMENTS
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